Inhibikase Therapeutics’ $18 Million IPO


Troutman Pepper Hamilton Sanders LLP advised Inhibikase Therapeutics, Inc. on the deal.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s Disease and related disorders that arise inside and outside of the brain, closed its initial public offering (IPO) of 1.8 million shares of common stock at a public price of $10 per share.

Inhibikase Therapeutics takes an innovative approach to developing therapeutics for halting and reversing the effects of neurodegenerative diseases inside and outside of the brain, including Parkinson’s disease. This approach targets the activation of c-Abl kinase, which the company believes play a significant role in the initiation and progression of neurodegenerative diseases and offers promise for those patients for whom current therapies have not worked.

The Troutman Pepper team was led by Merrill Kraines (Picture) and also included Todd Kornfeld, Judy O’Grady, Kirk Dungca, Bob Friedel, David Kaplan, Howard Shire, David Stauber, Michael Patané, Sheri Adler, Cagatay Akkoyun, Jennifer Lang, Dean Longfield, Kai Xi Wang, Abigail Yeo, Christina Boston and Noreen Onimus.

Involved fees earner: Sheri Adler – Troutman Pepper Hamilton Sanders LLP; Cagatay Akkoyun – Troutman Pepper Hamilton Sanders LLP; Christina Boston – Troutman Pepper Hamilton Sanders LLP; Kirk Dungca – Troutman Pepper Hamilton Sanders LLP; Robert Friedel – Troutman Pepper Hamilton Sanders LLP; David Kaplan – Troutman Pepper Hamilton Sanders LLP; Todd Kornfeld – Troutman Pepper Hamilton Sanders LLP; Merrill Kraines – Troutman Pepper Hamilton Sanders LLP; Jennifer Lang – Troutman Pepper Hamilton Sanders LLP; Judith O’Grady – Troutman Pepper Hamilton Sanders LLP; Michael Patané – Troutman Pepper Hamilton Sanders LLP; Howard Shire – Troutman Pepper Hamilton Sanders LLP; David Stauber – Troutman Pepper Hamilton Sanders LLP; Kai Xi Wang – Troutman Pepper Hamilton Sanders LLP; Abigail Yeo – Troutman Pepper Hamilton Sanders LLP; Dean Longfield – Troutman Sanders;

Law Firms: Troutman Pepper Hamilton Sanders LLP; Troutman Sanders;

Clients: Inhibikase Therapeutics, Inc.;

Author: Ambrogio Visconti